Symbols / SNSE Stock $29.11 -9.88% Sensei Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
SNSE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 39.04M
Enterprise Value 19.34M
Income -21.09M
Sales —
FCF (ttm) -12.61M
Book/sh 14.74
Cash/sh 15.81
Employees —
Insider 10d —
IPO Feb 04, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -25.99
PEG —
P/S —
P/B 1.98
P/C —
EV/EBITDA -0.87
EV/Sales —
Quick Ratio 4.98
Current Ratio 5.06
Debt/Eq 8.12
LT Debt/Eq —
EPS (ttm) -16.72
EPS next Y -1.12
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-30
Earnings (prior) 2026-03-30
ROA -40.81%
ROE -74.01%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.34M
Shs Float 810.86K
Insider Own 30.19%
Instit Own 13.06%
Short Float 92.38%
Short Ratio 12.01
Short Interest 855.82K
52W High 36.76
vs 52W High -20.81%
52W Low 5.26
vs 52W Low 453.42%
Beta -0.10
Impl. Vol. —
Rel Volume 0.31
Avg Volume 301.20K
Volume 93.61K
Target (mean) $50.00
Tgt Median $50.00
Tgt Low $50.00
Tgt High $50.00
# Analysts 1
Recom Buy
Prev Close $32.30
Price $29.11
Change -9.88%
About

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$50.00
Mean price target
2. Current target
$29.11
Latest analyst target
3. DCF / Fair value
$-169.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$29.11
Low
$50.00
High
$50.00
Mean
$50.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-30 down HC Wainwright & Co. Buy → Neutral —
2025-08-05 main HC Wainwright & Co. Buy → Buy $30
2025-03-28 main Oppenheimer Outperform → Outperform $4
2025-03-28 reit HC Wainwright & Co. Buy → Buy $4
2025-01-10 reit HC Wainwright & Co. Buy → Buy $4
2025-01-08 main HC Wainwright & Co. Buy → Buy $4
2024-08-07 reit HC Wainwright & Co. Buy → Buy $4
2024-05-24 reit HC Wainwright & Co. Buy → Buy $4
2024-05-24 reit Stephens & Co. Overweight → Overweight $5
2024-05-14 init Stephens & Co. — → Overweight $5
2023-12-04 init HC Wainwright & Co. — → Buy $4
2022-12-13 init Citigroup — → Buy $6
2022-10-03 up Oppenheimer Perform → Outperform $5
2022-03-10 main Piper Sandler — → Overweight $10
2021-07-01 down Berenberg Buy → Hold $12
2021-06-29 down Oppenheimer Outperform → Perform —
2021-03-01 init Oppenheimer — → Outperform $36
2021-03-01 init Piper Sandler — → Overweight $25
News
RSS: Latest SNSE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-09 PEYER JAMES Beneficial Owner of more than 10% of a Class of Security — 6,612 $7.92 $54,575
2025-12-09 PEYER JAMES Beneficial Owner of more than 10% of a Class of Security — 395 $6.40 $2,528
2025-12-09 CAMBRIAN BIOPHARMA INC Beneficial Owner of more than 10% of a Class of Security — 6,612 $7.92 $54,575
2025-12-09 CAMBRIAN BIOPHARMA INC Beneficial Owner of more than 10% of a Class of Security — 395 $6.40 $2,528
2025-12-05 PEYER JAMES Beneficial Owner of more than 10% of a Class of Security — 21,295 $9.06 $228,061
2025-12-05 CAMBRIAN BIOPHARMA INC Beneficial Owner of more than 10% of a Class of Security — 21,295 $9.06 $228,061
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
22.29
-29.61%
31.66
-14.57%
37.06
-26.15%
50.19
Research And Development
10.96
-41.16%
18.63
+1.79%
18.30
-39.77%
30.38
Selling General And Administration
11.33
-13.10%
13.04
-30.53%
18.77
-5.25%
19.80
General And Administrative Expense
11.33
-13.10%
13.04
-30.53%
18.77
-5.25%
19.80
Other Gand A
11.33
-13.10%
13.04
-30.53%
18.77
-5.25%
19.80
Total Expenses
22.29
-29.61%
31.66
-14.57%
37.06
-26.15%
50.19
Operating Income
-22.29
+29.61%
-31.66
+14.57%
-37.06
+26.15%
-50.19
Total Operating Income As Reported
-22.29
+31.66%
-32.61
+12.01%
-37.06
+26.15%
-50.19
EBITDA
-20.91
+27.24%
-28.75
+11.84%
-32.61
+30.66%
-47.02
Normalized EBITDA
-20.91
+24.75%
-27.79
+13.96%
-32.30
+31.30%
-47.02
Reconciled Depreciation
0.14
-89.49%
1.32
-2.15%
1.35
+0.30%
1.35
EBIT
-21.05
+29.98%
-30.07
+11.46%
-33.96
+29.80%
-48.37
Total Unusual Items
0.00
+100.00%
-0.95
-214.90%
-0.30
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-0.95
-214.90%
-0.30
0.00
Special Income Charges
0.00
+100.00%
-0.95
-214.90%
-0.30
0.00
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
0.95
0.00
—
Net Income
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Pretax Income
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Net Non Operating Interest Income Expense
1.21
-50.93%
2.46
-29.31%
3.48
+122.51%
1.56
Interest Expense Non Operating
0.03
-64.44%
0.09
-37.50%
0.14
-34.25%
0.22
Net Interest Income
1.21
-50.93%
2.46
-29.31%
3.48
+122.51%
1.56
Interest Expense
0.03
-64.44%
0.09
-37.50%
0.14
-34.25%
0.22
Interest Income Non Operating
1.24
-51.41%
2.55
-29.64%
3.62
+103.25%
1.78
Interest Income
1.24
-51.41%
2.55
-29.64%
3.62
+103.25%
1.78
Other Income Expense
-0.00
+99.58%
-0.95
-84.53%
-0.52
-1536.11%
0.04
Other Non Operating Income Expenses
-0.00
-33.33%
-0.00
+98.60%
-0.21
-697.22%
0.04
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Net Income From Continuing Operation Net Minority Interest
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Net Income From Continuing And Discontinued Operation
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Net Income Continuous Operations
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Normalized Income
-21.09
+27.81%
-29.21
+13.59%
-33.80
+30.44%
-48.59
Net Income Common Stockholders
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Diluted EPS
-16.72
+30.33%
-24.00
+1.64%
-24.40
+22.78%
-31.60
Basic EPS
-16.72
+30.33%
-24.00
+1.64%
-24.40
+22.78%
-31.60
Basic Average Shares
1.26
+0.39%
1.26
-10.14%
1.40
-8.96%
1.54
Diluted Average Shares
1.26
+0.39%
1.26
-10.14%
1.40
-8.96%
1.54
Diluted NI Availto Com Stockholders
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Gain On Sale Of PPE
—
0.00
+100.00%
-0.30
0.00
Line Item Trend 2023-12-31
Total Assets
74.37
Current Assets
67.25
Cash Cash Equivalents And Short Term Investments
65.76
Cash And Cash Equivalents
13.01
Other Short Term Investments
52.75
Prepaid Assets
1.17
Current Deferred Assets
—
Other Current Assets
0.33
Total Non Current Assets
7.12
Net PPE
7.04
Gross PPE
8.77
Accumulated Depreciation
-1.73
Properties
0.00
Machinery Furniture Equipment
0.53
Other Properties
7.98
Leases
0.25
Other Non Current Assets
0.09
Total Liabilities Net Minority Interest
9.48
Current Liabilities
5.64
Payables And Accrued Expenses
1.69
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
1.51
Current Debt And Capital Lease Obligation
2.44
Current Capital Lease Obligation
2.44
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
3.84
Long Term Debt And Capital Lease Obligation
3.77
Long Term Capital Lease Obligation
3.77
Other Non Current Liabilities
0.07
Preferred Securities Outside Stock Equity
—
Stockholders Equity
64.89
Common Stock Equity
64.89
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
1.25
Ordinary Shares Number
1.25
Treasury Shares Number
0.00
Additional Paid In Capital
297.00
Retained Earnings
-231.90
Gains Losses Not Affecting Retained Earnings
-0.21
Other Equity Adjustments
-0.21
Total Equity Gross Minority Interest
64.89
Total Capitalization
64.89
Working Capital
61.61
Invested Capital
64.89
Total Debt
6.21
Capital Lease Obligations
6.21
Net Tangible Assets
64.89
Tangible Book Value
64.89
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-20.45
+17.09%
-24.67
+22.96%
-32.02
+17.94%
-39.03
Cash Flow From Continuing Operating Activities
-20.45
+17.09%
-24.67
+22.96%
-32.02
+17.94%
-39.03
Net Income From Continuing Operations
-21.09
+30.08%
-30.16
+11.57%
-34.10
+29.82%
-48.59
Depreciation Amortization Depletion
0.14
-89.49%
1.32
-2.15%
1.35
+0.30%
1.35
Depreciation
0.14
-89.49%
1.32
-2.15%
1.35
+0.30%
1.35
Depreciation And Amortization
0.14
-89.49%
1.32
-2.15%
1.35
+0.30%
1.35
Other Non Cash Items
1.51
-2.83%
1.55
+14.52%
1.36
+13.65%
1.19
Stock Based Compensation
1.27
-59.36%
3.13
-29.61%
4.45
-23.37%
5.81
Asset Impairment Charge
0.00
-100.00%
0.95
0.00
—
Operating Gains Losses
—
—
0.30
+1106.67%
-0.03
Gain Loss On Investment Securities
—
—
—
-0.01
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.30
+2113.33%
-0.01
Change In Working Capital
-1.59
-225.56%
-0.49
+88.71%
-4.33
-529.56%
1.01
Change In Prepaid Assets
0.24
-64.99%
0.69
+801.01%
-0.10
+82.99%
-0.58
Change In Payables And Accrued Expense
0.23
+152.36%
-0.45
+80.91%
-2.33
-215.57%
2.02
Change In Accrued Expense
—
—
—
—
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
-0.56
-184.38%
0.67
+202.46%
-0.65
-191.68%
0.71
Change In Other Current Assets
0.08
-67.21%
0.24
+1009.09%
0.02
+340.00%
0.01
Change In Other Current Liabilities
-1.59
+3.76%
-1.65
-29.56%
-1.27
-11.48%
-1.14
Investing Cash Flow
19.77
-11.89%
22.44
-41.58%
38.41
-23.10%
49.95
Cash Flow From Continuing Investing Activities
19.77
-11.89%
22.44
-41.58%
38.41
-23.10%
49.95
Net PPE Purchase And Sale
0.23
+260.27%
-0.15
-942.86%
-0.01
+95.42%
-0.31
Purchase Of PPE
-0.02
+89.04%
-0.15
+18.89%
-0.18
+43.93%
-0.32
Sale Of PPE
0.25
0.00
-100.00%
0.17
+1006.67%
0.01
Capital Expenditure
-0.02
+89.04%
-0.15
+18.89%
-0.18
+43.93%
-0.32
Net Investment Purchase And Sale
19.54
-13.50%
22.59
-41.22%
38.43
-23.54%
50.26
Purchase Of Investment
-25.16
+43.59%
-44.59
-110.86%
-21.15
+54.88%
-46.87
Sale Of Investment
44.69
-33.47%
67.18
+12.77%
59.58
-38.66%
97.12
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Financing Cash Flow
-0.65
+18.04%
-0.79
+92.96%
-11.17
-3793.03%
-0.29
Cash Flow From Continuing Financing Activities
-0.65
+18.04%
-0.79
+92.96%
-11.17
-3793.03%
-0.29
Net Issuance Payments Of Debt
-0.65
+20.10%
-0.81
-6.57%
-0.76
-20.99%
-0.63
Issuance Of Debt
0.14
0.00
—
—
Repayment Of Debt
-0.79
+2.59%
-0.81
-6.57%
-0.76
-20.99%
-0.63
Long Term Debt Issuance
0.14
0.00
—
—
Long Term Debt Payments
-0.79
+2.59%
-0.81
-6.57%
-0.76
-20.99%
-0.63
Net Long Term Debt Issuance
-0.65
+20.10%
-0.81
-6.57%
-0.76
-20.99%
-0.63
Net Common Stock Issuance
-0.00
0.00
+100.00%
-10.38
0.00
Common Stock Payments
-0.00
0.00
+100.00%
-10.38
0.00
Repurchase Of Capital Stock
-0.00
0.00
+100.00%
-10.38
0.00
Proceeds From Stock Option Exercised
0.01
-79.41%
0.03
-29.17%
0.05
-85.96%
0.34
Net Other Financing Charges
-0.00
+70.00%
-0.01
+86.84%
-0.08
—
Changes In Cash
-1.33
+56.05%
-3.02
+36.94%
-4.78
-144.98%
10.64
Beginning Cash Position
9.99
-23.19%
13.01
-26.88%
17.80
+148.57%
7.16
End Cash Position
8.67
-13.27%
9.99
-23.19%
13.01
-26.88%
17.80
Free Cash Flow
-20.47
+17.52%
-24.82
+22.94%
-32.20
+18.16%
-39.35
Interest Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-0.70
+29.11%
-0.99
+6.63%
-1.06
-557.14%
0.23
Change In Interest Payable
—
—
—
—
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category